Dr. Jason M. Melear, M.D.

Medicare patients and services

Medicare patients, 2024

533

Services billed

90,536

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 29 companies reported 77 payments worth $43,644 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 32 industry-funded studies in 2025, from 13 companies. The companies reported $1,861,393 in research payments for these studies, mostly to the institutions running them.

• A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.…
  Amgen Inc.
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
  Beone Medicines Ltd. · Recruiting · NCT06742996
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
  Genentech, Inc.
• A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
  Novartis Pharmaceuticals Corporation
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
  AbbVie Inc. · Recruiting · NCT06428019
• A phase i dose escalation and expanded cohort study of PF06821497 in the treatment of adult patients with relapsedrefractory small cell lung cancer sclc castration resistant prostate cancer crpc and follicular lymphom…
  Pfizer Inc.
• Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
  Genentech, Inc.
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
  AbbVie Inc. · Active, not recruiting · NCT06667687
• A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
  Celgene Corporation
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin s Lymphoma
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Austin

• Miguel Albino, MD
• Nitya Alluri, MD
• Thomas L. Aung, M.D.
• Andrew J. Brenner, M.D., PH.D.
• Anna Capasso, MD
• Rene A. Castillo, MD
• Punit Chadha, MD
• John D. Doty, M.D.